Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
Barnaby HuntMichelle MocarskiWilliam J ValentineJakob LangerPublished in: Advances in therapy (2017)
Novo Nordisk A/S and Novo Nordisk Inc.